Review



compound ccrf-cem cem/adr5000  (CEM Corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    CEM Corporation compound ccrf-cem cem/adr5000
    Compound Ccrf Cem Cem/Adr5000, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+ccrf-cem/cem+adr5000+cells/pm38156413-269-0-2
    Average 90 stars, based on 1 article reviews
    compound ccrf-cem cem/adr5000 - by Bioz Stars, 2026-10
    90/100 stars

    Images

    Related Articles

    Inhibition:

    Article Title: Asymmetric Synthesis of Inhibitors of Glycinamide Ribonucleotide Transformylase
    Article Snippet: This indicates that these compounds, like 2 , inhibit cell growth by selectively inhibiting an enzyme within the purine biosynthetic (not pyrimidine) pathway consistent with their potent inhibition of GAR Tfase. table ft1 table-wrap mode="anchored" t5 caption a7 Compound CCRF-CEM (IC 50 , μM) (-) T, (-) H (+) T, (-) H (-) T, (+) H 10 R - 3 0.08 0.08 >10 10 S - 3 0.05 0.07 >10 10 R - 7 2.4 5.7 >10 10 S - 7 0.5 0.6 >10 10 R - 8 0.5 0.7 >10 10 S - 8 0.7 0.9 >10 9 >100 >100 >10 DDACTHF 2 2.7 0.016 3.6 0.017 >10 >10 Lometrexol 0.2 0.2 >10 Open in a separate window In vitro Cytotoxic Activity All seven inhibitors were subsequently examined in mutant CCRF-CEM cell lines that lack folypolyglutamate synthetase (CCRF-CEM/FPGS - ) or the reduced folate carrier (CCRF-CEM/MTX) ( ).

    In Vitro:

    Article Title: Asymmetric Synthesis of Inhibitors of Glycinamide Ribonucleotide Transformylase
    Article Snippet: This indicates that these compounds, like 2 , inhibit cell growth by selectively inhibiting an enzyme within the purine biosynthetic (not pyrimidine) pathway consistent with their potent inhibition of GAR Tfase. table ft1 table-wrap mode="anchored" t5 caption a7 Compound CCRF-CEM (IC 50 , μM) (-) T, (-) H (+) T, (-) H (-) T, (+) H 10 R - 3 0.08 0.08 >10 10 S - 3 0.05 0.07 >10 10 R - 7 2.4 5.7 >10 10 S - 7 0.5 0.6 >10 10 R - 8 0.5 0.7 >10 10 S - 8 0.7 0.9 >10 9 >100 >100 >10 DDACTHF 2 2.7 0.016 3.6 0.017 >10 >10 Lometrexol 0.2 0.2 >10 Open in a separate window In vitro Cytotoxic Activity All seven inhibitors were subsequently examined in mutant CCRF-CEM cell lines that lack folypolyglutamate synthetase (CCRF-CEM/FPGS - ) or the reduced folate carrier (CCRF-CEM/MTX) ( ).

    Activity Assay:

    Article Title: Asymmetric Synthesis of Inhibitors of Glycinamide Ribonucleotide Transformylase
    Article Snippet: This indicates that these compounds, like 2 , inhibit cell growth by selectively inhibiting an enzyme within the purine biosynthetic (not pyrimidine) pathway consistent with their potent inhibition of GAR Tfase. table ft1 table-wrap mode="anchored" t5 caption a7 Compound CCRF-CEM (IC 50 , μM) (-) T, (-) H (+) T, (-) H (-) T, (+) H 10 R - 3 0.08 0.08 >10 10 S - 3 0.05 0.07 >10 10 R - 7 2.4 5.7 >10 10 S - 7 0.5 0.6 >10 10 R - 8 0.5 0.7 >10 10 S - 8 0.7 0.9 >10 9 >100 >100 >10 DDACTHF 2 2.7 0.016 3.6 0.017 >10 >10 Lometrexol 0.2 0.2 >10 Open in a separate window In vitro Cytotoxic Activity All seven inhibitors were subsequently examined in mutant CCRF-CEM cell lines that lack folypolyglutamate synthetase (CCRF-CEM/FPGS - ) or the reduced folate carrier (CCRF-CEM/MTX) ( ).

    Mutagenesis:

    Article Title: Asymmetric Synthesis of Inhibitors of Glycinamide Ribonucleotide Transformylase
    Article Snippet: This indicates that these compounds, like 2 , inhibit cell growth by selectively inhibiting an enzyme within the purine biosynthetic (not pyrimidine) pathway consistent with their potent inhibition of GAR Tfase. table ft1 table-wrap mode="anchored" t5 caption a7 Compound CCRF-CEM (IC 50 , μM) (-) T, (-) H (+) T, (-) H (-) T, (+) H 10 R - 3 0.08 0.08 >10 10 S - 3 0.05 0.07 >10 10 R - 7 2.4 5.7 >10 10 S - 7 0.5 0.6 >10 10 R - 8 0.5 0.7 >10 10 S - 8 0.7 0.9 >10 9 >100 >100 >10 DDACTHF 2 2.7 0.016 3.6 0.017 >10 >10 Lometrexol 0.2 0.2 >10 Open in a separate window In vitro Cytotoxic Activity All seven inhibitors were subsequently examined in mutant CCRF-CEM cell lines that lack folypolyglutamate synthetase (CCRF-CEM/FPGS - ) or the reduced folate carrier (CCRF-CEM/MTX) ( ).



    Similar Products

    panel cell line compound leukemia ccrf cem 4 21 × 10  (ATCC)
    96
    ATCC panel cell line compound leukemia ccrf cem 4 21 × 10
    Panel Cell Line Compound Leukemia Ccrf Cem 4 21 × 10, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+ccrf-cem/CCRF-CEM/pm40003907-420-0-68
    Average 96 stars, based on 1 article reviews
    panel cell line compound leukemia ccrf cem 4 21 × 10 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    compound ccrf-cem cem/adr5000  (CEM Corporation)
    90
    CEM Corporation compound ccrf-cem cem/adr5000
    Compound Ccrf Cem Cem/Adr5000, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+ccrf-cem/cem+adr5000+cells/pm38156413-269-0-2
    Average 90 stars, based on 1 article reviews
    compound ccrf-cem cem/adr5000 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    panel cell line compound 15 compound 16 gi50 tgi lc50 gi50 tgi lc50 leukemia ccrf cem hl 60 tb k 562 molt 4 rpmi 8226 sr  (ATCC)
    99
    ATCC panel cell line compound 15 compound 16 gi50 tgi lc50 gi50 tgi lc50 leukemia ccrf cem hl 60 tb k 562 molt 4 rpmi 8226 sr
    Panel Cell Line Compound 15 Compound 16 Gi50 Tgi Lc50 Gi50 Tgi Lc50 Leukemia Ccrf Cem Hl 60 Tb K 562 Molt 4 Rpmi 8226 Sr, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+ccrf-cem/K-562/pmc10774712__RA___014___D3RA05401B___s001-137-1-61
    Average 99 stars, based on 1 article reviews
    panel cell line compound 15 compound 16 gi50 tgi lc50 gi50 tgi lc50 leukemia ccrf cem hl 60 tb k 562 molt 4 rpmi 8226 sr - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    ic 50 values obtained for these compounds in the sensitive cell line ccrf-cem  (CEM Corporation)
    90
    CEM Corporation ic 50 values obtained for these compounds in the sensitive cell line ccrf-cem
    Ic 50 Values Obtained For These Compounds In The Sensitive Cell Line Ccrf Cem, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+ccrf-cem/ic+50+values/pmc08472287-325-10-12
    Average 90 stars, based on 1 article reviews
    ic 50 values obtained for these compounds in the sensitive cell line ccrf-cem - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    t5 caption a7 panel cell line gi 50 compound panel cell line gi 50 compound 9i 9j 9i 9j leukemia melanoma ccrf cem  (ATCC)
    95
    ATCC t5 caption a7 panel cell line gi 50 compound panel cell line gi 50 compound 9i 9j 9i 9j leukemia melanoma ccrf cem
    <t> GI 50 </t> of compounds 9i and 9j against 59 cell lines in 9 different cancer panels tested using NCI’s in vitro five dose anticancer assay.
    T5 Caption A7 Panel Cell Line Gi 50 Compound Panel Cell Line Gi 50 Compound 9i 9j 9i 9j Leukemia Melanoma Ccrf Cem, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+ccrf-cem/CCRF-CEM/pmc06931042-125-78-143
    Average 95 stars, based on 1 article reviews
    t5 caption a7 panel cell line gi 50 compound panel cell line gi 50 compound 9i 9j 9i 9j leukemia melanoma ccrf cem - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    t5 caption a7 panel cell line compound 3a compound 3i gi 50 lc 50 gi 50 lc 50 leukemia cancer ccrf cem 3 06 100 100 100  (ATCC)
    99
    ATCC t5 caption a7 panel cell line compound 3a compound 3i gi 50 lc 50 gi 50 lc 50 leukemia cancer ccrf cem 3 06 100 100 100
    <t> GI 50 </t> of compounds 9i and 9j against 59 cell lines in 9 different cancer panels tested using NCI’s in vitro five dose anticancer assay.
    T5 Caption A7 Panel Cell Line Compound 3a Compound 3i Gi 50 Lc 50 Gi 50 Lc 50 Leukemia Cancer Ccrf Cem 3 06 100 100 100, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+ccrf-cem/K-562/pmc04400819-131-10-58
    Average 99 stars, based on 1 article reviews
    t5 caption a7 panel cell line compound 3a compound 3i gi 50 lc 50 gi 50 lc 50 leukemia cancer ccrf cem 3 06 100 100 100 - by Bioz Stars, 2026-10
    99/100 stars
    		  Buy from Supplier
    compounds 410 mmol l 1  (ATCC)
    95
    ATCC compounds 410 mmol l 1
    <t> GI 50 </t> of compounds 9i and 9j against 59 cell lines in 9 different cancer panels tested using NCI’s in vitro five dose anticancer assay.
    Compounds 410 Mmol L 1, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/compound+ccrf-cem/CCRF-CEM%3B+Leukemia%3B+Human/10__1016_slash_j__tet__2009__08__039-67-69-73
    Average 95 stars, based on 1 article reviews
    compounds 410 mmol l 1 - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    GI 50 of compounds 9i and 9j against 59 cell lines in 9 different cancer panels tested using NCI’s in vitro five dose anticancer assay.

    Journal: Bioorganic chemistry

    Article Title: New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity

    doi: 10.1016/j.bioorg.2018.10.064

    Figure Lengend Snippet: GI 50 of compounds 9i and 9j against 59 cell lines in 9 different cancer panels tested using NCI’s in vitro five dose anticancer assay.

    Article Snippet: The presence of such geometry might also be responsible for the absence of the 2-pyrazoline cyclization usually observed in hydrazide-chalcone reactions. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Fig. 2. caption a7 Possible stacking interaction for compound 9i . fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window Scheme 1. caption a7 Synthesis of ( E )- N’ -(( Z )-1-(4-aminophenyl)-3-phenylallylidene)-2-(phenyl)quinoline-4-carbohydrazide derivatives 9a-t . table ft1 table-wrap mode="anchored" t5 caption a7 Panel/cell line GI 50 Compound Panel/cell line GI 50 Compound 9i 9j 9i 9j Leukemia Melanoma CCRF-CEM 5.84 4.53 LOX IMVI 1.56 4.00 HL-60(TB) 2.54 3.49 MALME-3M > 100 > 100 K-562 1.05 3.09 M14 1.16 2.54 MOLT-4 3.30 3.23 MDA-MB-435 0.305 1.00 RPMI-8226 3.86 4.10 SK-MEL-2 2.03 3.81 SR 0.595 3.29 SK-MEL-28 3.78 6.23 Non-small cell lung cancer SK-MEL-5 0.701 2.50 A549/ATCC 2.33 4.79 UACC-257 > 100 33.7 EKVX 3.78 3.99 UACC-62 0.556 2.06 HOP-62 3.21 4.62 Ovarian cancer HOP-92 1.92 4.10 IGROV1 4.98 6.48 NCI-H226 7.54 6.47 OVCAR-3 0.462 2.98 NCI-H23 3.14 5.02 OVCAR-4 1.82 4.71 NCI-H322M 6.00 4.73 OVCAR-5 5.51 8.43 NCI-H460 1.89 3.51 OVCAR-8 4.16 5.25 NCI-H522 0.307 0.622 NCI/ADR-RES 0.519 2.54 Colon cancer SK-OV-3 3.32 4.94 COLO 205 1.99 2.80 Renal cancer HCC-2998 3.40 4.28 786–0 1.84 4.22 HCT-116 1.41 3.18 A498 0.375 1.64 HCT-15 1.03 3.33 ACHN 1.47 4.19 HT29 1.13 3.35 RXF 393 0.698 1.63 KM12 1.15 3.46 SN12C 4.27 6.84 SW-620 1.24 4.24 TK-10 52.30 8.51 CNS cancer UO-31 1.55 2.20 SF-268 2.19 4.09 SF-295 0.540 3.13 Breast cancer SF-539 1.41 2.43 MCF7 0.442 2.53 SNB-19 5.54 6.51 MDA-MB231/ATCC 3.28 3.94 SNB-75 0.371 1.41 HS 578T 1.05 4.68 U251 2.18 4.51 BT-549 2.04 3.92 Prostate cancer T-47D 2.70 2.73 PC-3 2.03 3.40 MDA-MB-468 2.95 4.91 DU-145 3.16 3.68 Open in a separate window GI 50 of compounds 9i and 9j against 59 cell lines in 9 different cancer panels tested using NCI’s in vitro five dose anticancer assay.

    Techniques: In Vitro